Taro Pharmaceuticals (TARO) was the winner of my ‘March Midness’  mid cap stock tournament, looking strong in every category examined—from growth to valuation. Now, without the conceit of the tournament, I wanted to take a closer look at TARO to determine if the company really has game.
To do this I revisited Taro’s financials and 20-F form, and consulted financial news, opinion pieces, and several reports from research firms. The firms invariably landed on the “buy” side of the spectrum, some more strongly than others, and largely due to the same quantitative factors that helped TARO win my tournament. Let’s take a look.